MRK Merck & Co., Inc. stock chart & analysis
Conviction 73HealthcareScan · Fri, Nov 6, 2026Merck & Co., Inc. (MRK) closed at $146.73 (-0.14%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 51, RS Rating 95, -6.5% from its 52-week high, +39.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
MRK technical analysis
Trend
MRK is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 0.3% above the 50-day ($146.36) and 15.0% above the 200-day ($127.65). ADX(14) at 19 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 51, in the bullish half of its range. MACD crossed above its signal line 5 sessions ago. Its RS Rating of 95 puts its weighted 12-month performance ahead of about 95% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $1.5B a day on average. ATR(14) is $4.77, 3.3% of price — its typical daily range. Bollinger Bands are in a squeeze (12 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (-0.12) shows distribution.
Key levels
The chart pattern's support is $138.97 and its resistance $153.31. The 52-week range is $84.35 to $156.92; price is 6.5% below the high and 74.0% above the low. The VWAP anchored at the 52-week high is $146.93, above price.
Performance
MRK returned -1.8% (1 week), +3.1% (1 month), +12.1% (3 months), +31.8% (6 months), +73.9% (1 year), +39.4% (year to date).
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Pharmaceutical Preparations · Listed 1949 · 75,000 employees
Congress activity
Disclosed STOCK Act trades in MRK · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Maria Elvira Salazar house · R · FL · traded 2026-09-24 | Sell | $1K–$15K | 2026-09-24 | 2026-10-07 | |
Maria Elvira Salazar house · R · FL · traded 2026-08-19 | Buy | $15K–$50K | 2026-08-19 | 2026-09-09 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Sell | $15K–$50K | 2026-03-27 | 2026-07-21 | |
 Gilbert Cisneros house · CA · traded 2025-12-19 | Buy | $1K–$15K | 2025-12-19 | 2026-01-09 | |
 Julie Johnson house · TX · traded 2025-12-18 | Sell | $1K–$15K | 2025-12-18 | 2026-01-05 | |
 Valerie Hoyle house · D · OR · traded 2025-09-23 | Sell | $1K–$15K | 2025-09-23 | 2025-10-10 | |
 Sheri Biggs house · R · SC · traded 2025-03-19 | Sell | $15K–$50K | 2025-03-19 | 2025-10-05 | |
Valerie Hoyle house · D · OR · traded 2024-10-29 | Buy | $1K–$15K | 2024-10-29 | 2025-09-12 | |
Gilbert Cisneros house · D · CA · traded 2025-08-05 | Buy | $1K–$15K | 2025-08-05 | 2025-09-12 | |
 Lisa McClain house · R · MI · traded 2025-08-04 | Sell | $1K–$15K | 2025-08-04 | 2025-09-12 |
Insider activity
SEC Form 4 transactions in MRK · open-market 9 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
DIAZ PAUL J Director · Phantom Stock · 2026-11-01 | Grant | 613.073 | $92K | 2026-11-01 | 2026-11-03 |
Guindo Chirfi EVP, Access, Policy & Comms · Common Stock · 2026-08-13 | Sell | 10K | $1.4M | 2026-08-13 | 2026-08-13 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-12 | Sell | 11.1K | $1.5M | 2026-08-12 | 2026-08-12 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-12 | Sell | 600 | $79K | 2026-08-12 | 2026-08-12 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-11 | Sell | 7.41K | $973K | 2026-08-11 | 2026-08-12 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-11 | Sell | 5.43K | $718K | 2026-08-11 | 2026-08-12 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-10 | Sell | 20.78K | $2.7M | 2026-08-10 | 2026-08-12 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-06 | Sell | 805 | $105K | 2026-08-06 | 2026-08-10 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-06 | Sell | 300 | $39K | 2026-08-06 | 2026-08-10 |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth · Common Stock · 2026-08-06 | Sell | 4.95K | $644K | 2026-08-06 | 2026-08-10 |
SEC filings
EDGAR filings in MRK · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.